MedTrace Logo

Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)

NCT01109121 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2011-01-06

No results posted yet for this study

Summary

This Phase 2 study will be a multicenter, double-blind, randomized, active-comparator study to evaluate the safety and efficacy of tranilast in combination with allopurinol in patients with hyperuricemia and moderate to severe gout.

Conditions

  • Moderate to Severe Gout
  • Hyperuricemia

Interventions

DRUG

Combination 400

Tranilast 300 mg QD; Allopurinol 400 mg QD

DRUG

Allopurinol

Allopurinol 400 mg, QD

DRUG

Combination 600

Tranilast, 300 mg QD; Allopurinol 600 mg QD

Sponsors & Collaborators

  • Nuon Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Director, Nuon Clinical Trials Group · Nuon Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2010-12-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01109121 on ClinicalTrials.gov